Evogene (NASDAQ:EVGN) reported a narrower net loss of approximately $1.8 million for the second quarter ended June 30, 2026, marking a significant improvement from the $4.7 million loss recorded during the same period in 2025. This financial shift coincides with a strategic restructuring focused on the company’s ChemPass AI platform, which is designed to accelerate small-molecule drug discovery and crop protection development.
Polina Ravzin, the company’s VP of Finance, attributed the improved bottom line to lower operating expenses, reduced losses from discontinued operations, and higher net financing income. The firm has aggressively reduced its headcount from 117 to 38 employees as part of a broader effort to streamline its internal operations and focus on core computational biology assets.
Chairman Nir Nimrodi addressed an ongoing proxy contest during the earnings call, urging shareholders to maintain the current board. Nimrodi stated that the board had previously attempted to integrate representatives from the dissident shareholder group, but those negotiations failed to yield a resolution. He argued that replacing the board during the current restructuring phase would jeopardize the company’s operational progress and strategic focus.
Management intends to appoint two new board members in September, provided the current board retains control. These nominees include Dr. Yael Margolin, an expert in pharmaceutical innovation, and Yoshinori Oyakawa, a veteran of the international biotechnology sector. The company expects total cash usage for 2026 to fall between $8.5 million and $9.5 million, a sharp decline from the $20.5 million utilized in 2024.
President and CEO Ofer Haviv reported that Evogene has signed four new drug-development agreements since the beginning of 2026, bringing the total number of active collaborations to six. Two of these partnerships have successfully completed the initial hit identification stage of the ChemPass AI workflow. Haviv noted that validation results from these projects have exceeded partner expectations, prompting the company to initiate discussions with larger pharmaceutical firms alongside its existing biotechnology partners.
The company has expanded its virtual chemical space from 36 billion to 110 billion molecules, leveraging a second agreement with Google Cloud to integrate AI agents that automate complex research tasks. These tools have reduced the time required for specific research functions from months to minutes, according to management. In the agricultural sector, the firm is currently conducting lead optimization for a fungicide program targeting Septoria, with greenhouse testing expected to precede future field trials.
The shift toward a leaner operational model has involved the cessation or transition of several non-core business units. Lavie Bio is no longer operational following a transaction with ICL, while Biomica has ceased operations after licensing its oncology candidate, BMC128, to Lishan Pharmaceuticals. Casterra has also reduced its operational footprint to focus exclusively on the Brazilian market.
The company’s financial position remains a focal point for investors as it navigates this transition. As of June 30, Evogene held approximately $9.3 million in consolidated cash and cash equivalents. The firm raised $800,000 through an at-the-market equity program during the second quarter and an additional $2.4 million in the third quarter.
Research and development expenses for the second quarter were $1.4 million, down from $1.7 million in the prior-year period. General and administrative costs also saw a decline, falling to $900,000 from the previous $1 million. These reductions underscore the company’s commitment to preserving capital while scaling its computational biology platform for future commercial applications.
Analysts will be watching the upcoming board election results to determine the future direction of the company’s leadership. The ability of the current management team to secure further R&D funding through collaboration fees remains a critical milestone for long-term sustainability. Future developments will depend on the successful translation of the ChemPass AI platform into viable preclinical candidates and the continued monetization of remaining non-core assets.
